// App-Quantinova.ai

9063 : Cumulative incidence rates for CNS and non-CNS progression by baseline CNS metastases status using data from two alectinib phase II studies.

Researchers

Presenter

  • Shirish M. Gadgeel

Principal Investigators

  • Alice Tsang Shaw

  • Fabrice Barlesi

  • Lucio Crino

  • James Chih-Hsin Yang

  • Anne-Marie C. Dingemans

  • Dong-Wan Kim

  • Filippo De Marinis

  • Mathias Schulz

  • Shiyao Liu

  • Susan Meredith Fish

  • Ahmed Kotb

  • Sai-Hong Ignatius Ou

Medical Centers

  • Karmanos Cancer Institute, Detroit, MI

  • Massachusetts General Hospital, Boston, MA

  • Aix-Marseille University, Assistance Publique Hopitaux de Marseille, Marseille, France

  • Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy

  • National Yang-Ming University, Taipei, Taiwan

  • Maastricht University Medical Center, Maastricht, Netherlands

  • IEO, Milan, Italy

  • Genentech, Inc., South San Francisico, CA

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • University of California, Irvine, Fullerton, CA

Locations

  • Taiwan

  • Italy

  • Netherlands

  • Switzerland

  • United States

  • France

Companies

  • Genentech, Inc.

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

Drug/Treatment

  • Crizotinib

  • Alectinib

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • II

Study Id's

  • NCT01801111

  • NCT01871805

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved